US Patent

US7695734 — Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2028-04-26 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof.

USPTO Abstract

An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.

Drugs covered by this patent

pramipexole-dihydrochloride (PRAMIPEXOLE DIHYDROCHLORIDE)

Patent Metadata

Patent number: US7695734
Jurisdiction: US
Classification: Formulation
Expires: 2028-04-26
Drug substance claim: No
Drug product claim: Yes
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.